| 1 | EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma | Journal of Hepatology | 2018 | 6,206 |
| 2 | EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma | Journal of Hepatology | 2012 | 4,083 |
| 3 | Histological grading and staging of chronic hepatitis | Journal of Hepatology | 1995 | 4,024 |
| 4 | EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection | Journal of Hepatology | 2017 | 3,876 |
| 5 | EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease | Journal of Hepatology | 2016 | 3,224 |
| 6 | A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement | Journal of Hepatology | 2020 | 3,158 |
| 7 | BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update | Journal of Hepatology | 2022 | 2,971 |
| 8 | Burden of liver diseases in the world | Journal of Hepatology | 2019 | 2,607 |
| 9 | Expanding consensus in portal hypertension | Journal of Hepatology | 2015 | 2,234 |
| 10 | Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies | Journal of Hepatology | 2006 | 2,173 |
| 11 | EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection | Journal of Hepatology | 2012 | 2,154 |
| 12 | EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis | Journal of Hepatology | 2018 | 1,993 |
| 13 | Baveno VII – Renewing consensus in portal hypertension | Journal of Hepatology | 2022 | 1,962 |
| 14 | The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide | Journal of Hepatology | 2006 | 1,735 |
| 15 | The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis | Journal of Hepatology | 2019 | 1,616 |
| 16 | The gut-liver axis in liver disease: Pathophysiological basis for therapy | Journal of Hepatology | 2020 | 1,613 |
| 17 | Non-alcoholic fatty liver disease – A global public health perspective | Journal of Hepatology | 2019 | 1,582 |
| 18 | Global burden of primary liver cancer in 2020 and predictions to 2040 | Journal of Hepatology | 2022 | 1,557 |
| 19 | Global burden of liver disease: 2023 update | Journal of Hepatology | 2023 | 1,557 |
| 20 | Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030 | Journal of Hepatology | 2018 | 1,413 |
| 21 | EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update | Journal of Hepatology | 2021 | 1,340 |
| 22 | EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis | Journal of Hepatology | 2015 | 1,326 |
| 23 | Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease | Journal of Hepatology | 2015 | 1,286 |
| 24 | Classification of chronic viral hepatitis: a need for reassessment | Journal of Hepatology | 1991 | 1,271 |
| 25 | EASL Clinical Practice Guidelines: Management of chronic hepatitis B | Journal of Hepatology | 2009 | 1,266 |
| 26 | EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) | Journal of Hepatology | 2024 | 1,232 |
| 27 | EASL Clinical Practice Guidelines: Management of cholestatic liver diseases | Journal of Hepatology | 2009 | 1,216 |
| 28 | EASL Recommendations on Treatment of Hepatitis C 2018 | Journal of Hepatology | 2018 | 1,205 |
| 29 | Revising consensus in portal hypertension: Report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension | Journal of Hepatology | 2010 | 1,170 |
| 30 | EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis | Journal of Hepatology | 2010 | 1,155 |
| 31 | Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma | Journal of Hepatology | 2022 | 1,154 |
| 32 | Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy | Journal of Hepatology | 2003 | 1,109 |
| 33 | Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma | Journal of Hepatology | 2014 | 1,073 |
| 34 | EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis | Journal of Hepatology | 2017 | 1,063 |
| 35 | Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis | Journal of Hepatology | 2016 | 993 |
| 36 | Treatment of NAFLD with diet, physical activity and exercise | Journal of Hepatology | 2017 | 963 |
| 37 | Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis | Journal of Hepatology | 2017 | 934 |
| 38 | Endoplasmic reticulum stress in liver disease | Journal of Hepatology | 2011 | 918 |
| 39 | Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors | Journal of Hepatology | 2008 | 895 |
| 40 | EASL Clinical Practice Guidelines: Autoimmune hepatitis | Journal of Hepatology | 2015 | 895 |
| 41 | NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice | Journal of Hepatology | 2017 | 884 |
| 42 | Cirrhosis-associated immune dysfunction: Distinctive features and clinical relevance | Journal of Hepatology | 2014 | 871 |
| 43 | The burden of liver disease in Europe: A review of available epidemiological data | Journal of Hepatology | 2013 | 853 |
| 44 | EASL recommendations on treatment of hepatitis C: Final update of the series☆ | Journal of Hepatology | 2020 | 851 |
| 45 | Criteria of drug-induced liver disorders | Journal of Hepatology | 1990 | 843 |
| 46 | Macrophage heterogeneity in liver injury and fibrosis | Journal of Hepatology | 2014 | 830 |
| 47 | EASL Recommendations on Treatment of Hepatitis C 2015 | Journal of Hepatology | 2015 | 830 |
| 48 | Altered profile of human gut microbiome is associated with cirrhosis and its complications | Journal of Hepatology | 2014 | 827 |
| 49 | Complications following percutaneous liver biopsy | Journal of Hepatology | 1986 | 825 |
| 50 | EASL Clinical Practice Guidelines: Wilson’s disease | Journal of Hepatology | 2012 | 823 |